文献速递慢阻肺哮喘

保留比值受损肺功能(PRISm)的患病率、危险因素与临床意义:英国生物银行队列分析

Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis.
PubMed 文献 · Lancet Respir Med · 2021-11-02

纵向分析显示部分PRISm患者可进展为气流阻塞。

要点

  • PRISm与呼吸困难、心血管疾病及全因死亡风险升高独立相关。
  • 部分PRISm患者可进展为气流阻塞,需识别高风险个体。

核心结论

  • PRISm与呼吸困难、多病共存及死亡风险增加相关,且不能完全由吸烟、肥胖或已有肺病解释。
  • 尽管许多PRISm患者呈短暂性,但识别进展为肺功能异常的高风险个体具有重要意义。

研究设计与样本

  • 生存分析覆盖12年期间。

主要发现

  • 其他危险因素包括女性、超重、躯干脂肪量及躯干脂肪百分比。

临床怎么用

  • 对肺功能提示PRISm的成人,应评估呼吸困难、心血管疾病等合并症及死亡风险。
  • 管理PRISm患者时需关注肥胖、吸烟及哮喘等可干预因素,并监测肺功能进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preserved ratio impaired spirometry (PRISm) is defined as a FEV1 of less than 80% predicted and a FEV1/forced vital capacity (FVC) ratio of 0·70 or higher. Previous research has indicated that PRISm is associated with respiratory symptoms and is a precursor of chronic obstructive pulmonary disease (COPD). However, these findings are based on relatively small selective cohorts with short follow-up. We aimed to determine the prevalence, risk factors, clinical implications, and mortality of PRISm in a large adult general population. METHODS: For this cohort analysis, we used data from the UKBiobank to assess PRISm prevalence, risk factors and associated symptoms, and associated comorbidities in a large adult population. Participants with spirometry deemed acceptable by an investigator (best measure FEV1 and FVC values) at baseline were included. Participants were excluded if they did not have acceptable spirometry or were missing data on body-mass index or smoking status. Control spirometry was defined as a FEV1 of 80% or more predicted and a FEV1/FVC ratio of 0·70 or higher. Airflow obstruction was defined as a FEV1/FVC ratio of less than 0·70. We used multivariable regression to determine risk factors for PRISm and associated comorbidities. Individuals who lived within close proximity to an assessment centre were invited for follow-up, with repeat spirometry. Only participants who had been included at baseline were examined in follow-up. This allowed for a longitudinal analysis of PRISm over time and risk factors for transition to airflow obstruction. We also did the survival analysis for a 12-year period. FINDINGS: Participants were recruited by UK Biobank between Dec 19, 2006, and Oct 10, 2010. We included 351 874 UK Biobank participants (189 247 women and 162 627 men) in our study, with a median follow-up of 9·0 years (IQR 8·0-10·0). 38 639 (11·0%) of 351 874 participants had PRISm at baseline. After adjustment, PRISm was strongly associated with obesity (odds ratio [OR] 2·40 [2·26-2·55], p<0·0001), current smoking (1·48 [1·36-1·62], p<0·0001), and patient reported doctor-diagnosed asthma (1·76 [1·66-1·88], p<0·0001). Other risk factors identified included female sex, being overweight, trunk fat mass, and trunk fat percentage. PRISm was strongly associated with symptoms and comorbidity including increased risk of breathlessness (adjusted OR 2·0 [95% CI 1·91-2·14], p<0·0001) and cardiovascular disease (adjusted OR 1·71 [1·64-1·83], p<0·0001 for heart attack). Longitudinal analysis showed that 241 (12·2%) of 1973 participants who had PRISm at baseline had transitioned to airflow obstruction consistent with COPD. PRISm was associated with increased all-cause mortality (adjusted hazard ratio 1·61 [95% CI 1·53-1·69], p<0·0001) versus control participants. INTERPRETATION: PRISm was associated with breathlessness, multimorbidity, and increased risk of death, which does not seem to be explained by smoking, obesity, or existing lung disease. Although for many patients PRISm is transient, it is important to understand which individuals are at risk of progressive lung function abnormalities. Further research into the genetic, structural and functional pathophysiology of PRISm is warranted. FUNDING: UK Medical Research Council and University of Bristol.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Higbee DH, Granell R, Davey Smith G, et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med. 2021. PMID: 34739861. doi:10.1016/S2213-2600(21)00369-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。